Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

Peer Review reports

Original Submission
23 Dec 2021	Submitted	Original manuscript
24 Dec 2021	Reviewed	Reviewer Report
26 Dec 2021	Reviewed	Reviewer Report - Shebli Atrash
2 Jan 2022	Reviewed	Reviewer Report - Frederik Schjesvold
3 Jan 2022	Reviewed	Reviewer Report
4 Jan 2022	Reviewed	Reviewer Report
2 Feb 2022	Author responded	Author comments - Lugui Qiu
Resubmission - Version 2
2 Feb 2022	Submitted	Manuscript version 2
2 Feb 2022	Reviewed	Reviewer Report - Shebli Atrash
3 Feb 2022	Reviewed	Reviewer Report
17 Feb 2022	Author responded	Author comments - Lugui Qiu
Resubmission - Version 3
17 Feb 2022	Submitted	Manuscript version 3
Publishing
18 Feb 2022	Editorially accepted
5 Apr 2022	Article published	10.1186/s12916-022-02305-4

Back to article page